Together with the Selection Guide "MagSi beads for genomic application", the MagSi-DNA kit allows our clients to make the right choice by testing different prodcuts in an easy way. A complete set of the 6 types of MagSi beads for genomic applications, offered in a single kit for trial purposes in development of new assays and kits. It includes MagSi-DNA, MagSi-DNA COOH, MagSi-DNA allround, MagSi-DNA allround COOH, MagSi-DNA 600 and MagSi-DNA 600 COOH.

The MagSi-DNA kit enables you to evaluate:

• the physical properties of different bead types
• the Specifications of MagSi Beads
• the Compatibility of MagSi Beads with different buffer systems
• the prodcut features of the MagSi-DNA 600 and MagSi-DNA 600 COOH beads.....

Download technical documentation

MagSi-DNA

Ultra-fast magnetic silica particles with instant magnetic separation and short suspension time. Intended for nucleic acid isolation from various sources (blood, cells, bacteria etc.) for manual and automated work-flow.

MagSi-DNA COOH

Magnetic silica particles with instant magnetic separation and short suspension time. Intended for nucleic acid isolation from various sources (blood, cells, bacteria etc.) for manual and automated work-flow. Under specific conditions, the carboxylated surface enables higher yield and purity from samples.

MagSi-DNA allround

Ultra-fast magnetic silica beads with optimized magnetic content for fast separation and long suspension time without mixing. Intended for nucleic acid isolation from various sources (blood, cells, bacteria etc.) for manual and automated workflow.

MagSi-DNA allround COOH

Magnetic silica beads with optimized magnetic content for fast separation and long suspension time without mixing. Intended for nucleic acid isolation from various sources (blood, cells, bacteria etc.) for manual and automated work-flow Under specific conditions, the carboxylated surface enables higher yield and purity from samples.

MagSi-DNA 600
Magnetic silica beads with large surface area and optimized magnetic content for long suspension time. Intended for nucleic acid isolation from various sources (blood, cells, bacteria etc.) for manual and automated work-flow.

MagSi-DNA 600 COOH
Magnetic silica beads with large surface area and optimized magnetic content for long suspension time. Intended for nucleic acid isolation from various sources (blood, cells, bacteria etc.) for manual and automated work-flow. Under specific conditions, the carboxylated surface enables higher yield and purity from samples.

For quantitative determination of acetylcholinesterase activity and evaluation of acetylcholinesterase inhibitors.

Method: OD412nm.
Samples: blood, serum, plasma etc.
Species: all.
Procedure: 10 min.
Size: 100 tests.
Detection limit: 10 U/L.

DESCRIPTION

ACETYLCHOLINESTERASE (EC 3.1.1.7, AChE), also known as RBC
cholinesterase, is found primarily in the blood and neural synapses.
Low serum cholinesterase activity may relate to exposure to
insecticides or to one of a number of variant genotypes. AChE
catalyzes the hydrolysis of the neurotransmitter acetylcholine into
choline and acetic acid, a reaction necessary to allow a cholinergic
neuron to return to its resting state after activation. Cholinesterase
levels of cells and plasma are used as a guide in establishing safety
precautions relative to exposure and contact, as well as a guide in
determining the need for workers to be removed from areas of contact
with the organic phosphate insecticides.
Simple, direct and automation-ready procedures for measuring AChE
activity are very desirable. BioAssay Systems' QuantiChromTM
Acetylcholinesterase Assay is based on an improved Ellman method,
in which thiocholine produced by the action of acetylcholinesterase
forms a yellow color with 5,5’-dithiobis(2-nitrobenzoic acid). The
intensity of the product color, measured at 412 nm, is proportionate to
the enzyme activity in the sample.

APPLICATIONS

Direct assays of acetylcholinesterase activity in blood, serum, plasma,
and other biological samples. Evaluation of acetylcholinesterase
inhibitors.

KEY FEATURES

Sensitive and accurate. Detection range 10 to 600 U/L AChE activity
in 96-well plate assay.
Convenient. The procedure involves adding a single working reagent,
and reading the optical density at 2 min and 10 min at room
temperature.
High-throughput. Can be readily automated as a high-throughput 96-
well plate assay for thousands of samples per day.

KIT CONTENTS

(100 tests in 96-well plates)
Assay Buffer (pH 7.5): 30 mL Reagent: 240 mg
Calibrator: 4 mL (equivalent to 200 U/L)

Storage conditions. The kit is shipped at room temperature. Store all
reagents at room temperature. Shelf life: 6 months after receipt.
Precautions: reagents are for research use only. Normal precautions
for laboratory reagents should be exercised while using the reagents.

MATERIALS REQUIRED, BUT NOT PROVIDED

Pipeting (multi-channel) devices. Clear-bottom 96-well plates (e.g.
Corning Costar) and plate reader.

Sample Type: cerebral cortical tissues

Species:  rat

References: Basselin, M et al (2009). Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats. J Alzheimers Dis. 17(2):369-82

Pubmed ID: 19363262

Pubmed link: http://www.ncbi.nlm.nih.gov/pubmed?term=19363262

Abstract:

Donepezil, an acetylcholinesterase (AChE) inhibitor used for treating Alzheimer's disease patients, is thought to act by increasing brain extracellular acetylcholine (ACh), and ACh binding to cholinergic receptors. Muscarinic receptors are coupled to cytosolic phospholipase A2 (cPLA2) activation and arachidonic acid (AA) release from synaptic membrane phospholipid. This activation can be imaged in rodents as an AA incorporation coefficient k*, using quantitative autoradiography. Acute and chronic effects of donepezil on the AA signal, k* for AA, were measured in 81 brain regions of unanesthetized rats. Twenty min after a single oral dose (3.0 mg/kg) of donepezil, k* was increased significantly in 37 brain regions, whereas k* did not differ from control 7 h afterwards or following chronic (21 days) of donepezil. Pretreatment with atropine prevented the 20-min increments in k* following donepezil. Donepezil also increased the brain ACh concentration and reduced brain AChE activity, but did not change cPLA2 activity, regardless of administration regimen. These results show that donepezil acutely increases the brain AA signal that is mediated by ACh acting at muscarinic receptors, but that this signal is rapidly desensitized despite continued elevated brain ACh concentration. In contrast, the AA signal in response to arecoline was not altered following donepezil.

 [PubMed - indexed for MEDLINE] PMCID: PMC2790024

Sample Type: serum

Species:  human

References: Al-Akwa, AA et al (2009). Free radicals are present in human serum of Catha edulis Forsk (Khat) abusers. J Ethnopharmacol. 125(3):471-3

Pubmed ID: 19619634

Pubmed link: http://www.ncbi.nlm.nih.gov/pubmed?term=19619634

Abstract:

OBJECTIVE: Khat (Catha edulis Forsk) is a naturally occurring drug with an amphetamine-like structure and action. It has been postulated that amphetamine induces free radical formation. On this basis, we have hypothesized that Khat may promote synthesis of reactive oxygen and nitrogen species in the same way that amphetamine promotes free radical production.

MATERIALS AND METHODS: Forty male subjects were enrolled in two groups: those with a chronic Khat chewing habit (n=20), and those without a chewing habit (controls; n=20). Both groups were matched with regard to age. Total antioxidant capacity and cholinesterase (AChE) activity were assayed.

RESULTS: This study showed that Khat consumption inhibited serum free radical scavenging enzymes, resulting in significant elevations in free radical loads (p=0.01; n=20). We also showed that serum acetyl cholinesterase (AChE) was significantly inhibited in the Khat chewing group (p=0.002; n=20).

CONCLUSION: These results show for the first time that Khat may contribute to high levels of free radicals. In addition, the presence of pesticides in Khat leaves is implicated in the inhibition of AChE activity.

 [PubMed - indexed for MEDLINE]

Sample Type: explanted atria

Species:  dog

References: Ng, J et al (2011). Autonomic remodeling in the left atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation. Circ Arrhythm Electrophysiol.4(3):388-96

Pubmed ID: 21421805

Pubmed link: http://www.ncbi.nlm.nih.gov/pubmed?term=21421805

Abstract:

BACKGROUND: Atrial fibrillation (AF) is commonly associated with congestive heart failure (CHF). The autonomic nervous system is involved in the pathogenesis of both AF and CHF. We examined the role of autonomic remodeling in contributing to AF substrate in CHF.

METHODS AND RESULTS: Electrophysiological mapping was performed in the pulmonary veins and left atrium in 38 rapid ventricular-paced dogs (CHF group) and 39 control dogs under the following conditions: vagal stimulation, isoproterenol infusion, ?-adrenergic blockade, acetylcholinesterase (AChE) inhibition (physostigmine), parasympathetic blockade, and double autonomic blockade. Explanted atria were examined for nerve density/distribution, muscarinic receptor and ?-adrenergic receptor densities, and AChE activity. In CHF dogs, there was an increase in nerve bundle size, parasympathetic fibers/bundle, and density of sympathetic fibrils and cardiac ganglia, all preferentially in the posterior left atrium/pulmonary veins. Sympathetic hyperinnervation was accompanied by increases in (1)-adrenergic receptor R density and in sympathetic effect on effective refractory periods and activation direction. ?-Adrenergic blockade slowed AF dominant frequency. Parasympathetic remodeling was more complex, resulting in increased AChE activity, unchanged muscarinic receptor density, unchanged parasympathetic effect on activation direction and decreased effect of vagal stimulation on effective refractory period (restored by AChE inhibition). Parasympathetic blockade markedly decreased AF duration.

CONCLUSIONS: In this heart failure model, autonomic and electrophysiological remodeling occurs, involving the posterior left atrium and pulmonary veins. Despite synaptic compensation, parasympathetic hyperinnervation contributes significantly to AF maintenance. Parasympathetic and/or sympathetic signaling may be possible therapeutic targets for AF in CHF.

 [PubMed - indexed for MEDLINE]

More Enzyme Activity products:

Even more: Enzychrom products

The 3-D Spheroid Colorimetric Proliferation/Viability Assay provides a useful tool for modeling tumor response in vitro. The kit utilizes a 3-D Culture Qualified 96 Well Spheroid Formation Plate alongside a specialized Spheroid Formation ECM to drive aggregation and/or spheroid formation of cells. Upon completion of spheroid formation, the spheroid may be treated with pharmacological agents to evaluate tumor viability after drug treatment. Tumor spheroid expansion is visualized microscopically and can be quantitated through image analysis software for real-time and label free evaluation. At the conclusion of the assay, cell viability may be assessed by absorbance using MTT. The 3-D Spheroid Colorimetric Proliferation/Viability Assay offers an in vitro, standardized, threedimensional, high content format for inducing multicellular tumor spheroid (MCTS) formation and quantitating cell viability within the spheroids in response to pharmacological treatment.

Catalog Number: 9125 (25-50 tests)

Quick Overview

Forget the lysates. Assay for apoptosis via caspase-3 activity in whole, living cells with the FLICA® 660 Caspase-3 Assay Kit.
- Ex: 660 nm / Em: 680-690 nm
- Whole cell analysis via flow cytometry or fluorescence microscopy
- Flexible multiparametric analysis with additional dyes or probes
- Compatibility with GFP and green autofluorescence
- Benchtop flow compatible

This new caspase-3 assay for in vitro apoptosis detection employs a new far-red fluorescent caspase-3 and -7 inhibitor probe, FLICA® 660-DEVD-FMK, to label active caspase-3 and-7 enzymes in living cells or tissue samples. Image the fluorescent signal using fluorescence microscopy or analyze samples for caspase-3 and -7 activity by flow cytometry.

The cell permeant FLICA caspase-3 detection probe, 660-DEVD-FMK, is comprised of a caspase-3-affinity inhibitor peptide sequence (DEVD) and a fluoromethyl ketone (FMK) moiety that enable an irreversible, covalent binding event with active caspase enzymes. This newest FLICA caspase probe is labeled with a far-red fluorescent 660 dye reporter, enabling caspase-3 detection via common fluorescence detection methods.

Apoptosis detected in induced Jurkat cells by labeling active caspases 3&7 with far-red fluorescent FLICA 660 Caspase 3/7 Assay

Promotional price: 199$

Quick Overview:
Quantitative assay of adipolysis by measuring glycerol released in cell culture using colorimetric (570nm) or fluorimetric (530nm/590nm) methods. Procedure: 20 min. Detection limit: 0.92 g/mL. Shelf life: 3 months. Shipping: on ice; storage: 4, -20C.

Description:

Obesity is a chronic condition that develops from storage of excessive energy in the form of adipose tissue. The resulting adiposity presents a high risk factor for diseases such as type 2 diabetes, cardiovascular diseases, and cancer. ADIPOLYSIS or lipolysis is a  ighly regulated process in fat metabolism, in which triglycerides are broken down into glycerol and free fatty acids. Rapid, robust and accurate procedures for adipolysis quantification in cell culture are very useful in research and drug discovery. BioAssay Systems'  dipolysis assay kit directly measures glycerol released during adipolysis. This homogeneous assay uses a single Working Reagent that combines glycerol kinase, glycerol phosphate oxidase and color reactions in one step. The color intensity of the reaction product  t 570nm is directly proportional to glycerol concentration in the sample.

Applications:

- Direct Assays: adipolysis (glycerol in cell culture media).
- Drug Discovery/Pharmacology: effects of testing drugs on adipolysis.

Cat. No.: EAPL-200

Quantity / Size: 200 Tests

Kit Contents:

Assay Buffer: 24 mL Enzyme Mix: 500 μL ATP: 250 μL Dye Reagent: 220 μL Standard: 100 μL 100 mM Glycerol Storage conditions. The kit is shipped on ice. Store Assay Buffer at 4°C and other reagents at -20°C. Shelf life of 12 months after receipt. Precautions:  eagents are for research use only. Normal precautions for laboratory reagents should be exercised while using the reagents. Please refer to Material Safety Data Sheet for detailed information.

Benefits:

- Assay kit that are simple, convenient and cost effective

- Superior in performance

- Researchers need little-to-notime for assay optimization

- Specialize for both routine laboratory tests and for high-throughput drug discovery applications

- with a focus on safe, non-radioactive assay

Key Features: Key features of our assays include simplicity, high-throughput, sensitivity, accuracy and low interference.

Storage Temp: -20°C

Shipping Conditions: Dry Ice

Download Datasheet

The Cysticercosis Antigen (Ag) ELISA (Ref. 650501) is a sandwich Enzyme-Linked ImmunoSorbent Assay based on monoclonal antibodies for the qualitative determination of viable metacestodes (cysticerci) of Taenia spp. in human and porcine serum samples.

-  Analytical sensitivity: 1 cyst is detectable in certain conditions
- Incubation times: assay 45 minutes + sample prep <30 minutes
- Available format: 96T

Taenia solium cysticercosis is an infection of humans and pigs with metacestode larvae (cysticercus) of Taenia solium. Circulating antigen detection in serum is an important diagnostic method that indicates the presence of viable parasites. The monoclonal antibodies used in this assay are produced against excretory secretory products (ESP) of viable T. saginata cysticerci. The glycoprotein antigens detected by these monoclonal antibodies are present on the tegument and in the excretory secretory products of metacestodes.

The assay demonstrates the presence of viable cysticerci only, it does not detect degenerated or calcified cysticerci. In this respect, unlike antibody detection, measurement of circulating antigen levels allows differentiation of cysticercosis cases with viable parasites, with antigen levels correlating to the numbers and size of lesions. It can as such also provide a tool for serological monitoring of antiparasitic therapy in human or pigs: antigen levels drop rapidly after successful anthelminthic treatment.

Porcine cysticercosis

The assay is genus specific, not species specific. The assay does not allow the differentiation between infections of different Taenia species in pigs. In experimentally infected pigs, circulating antigens were first detected between 2 and 6 weeks post infection and remained present generally throughout an observation period of 6 months, even in pigs carrying only five to eight living cysts. The minimum number of living cysts, that could be detected using the Cysticercosis Ag ELISA, was one.

Human cysticercosis

Because T. solium is the only Taenia sp. causing cysticercosis in man, the test is specific. No cross-reactions were observed with sera from patients with other parasitologically and/or serologically confirmed infections. The sensitivity of the assay decreases when the number of viable cysts is low; infections with one viable cyst are often not detectable. Antigen levels are generally higher in extraparenchymal neurocysticercosis (NCC) (particularly subarachnoid NCC) than in intraparenchymal NCC; therefore, high antigen levels should lead one to suspect the presence of extraparenchymal NCC.

Download datasheet

Catalog number : DIUR-500
Quantity: 500 tests
Availability: Yes

DESCRIPTION:
Urea is primarily produced in the liver and secreted by the kidneys. Urea
is the major end product of protein catabolism in animals. It is the
primary vehicle for removal of toxic ammonia from the body. Urea
determination is very useful for the medical clinician to assess kidney
function of patients. In general, increased urea levels are associated with
nephritis, renal ischemia, urinary tract obstruction, and certain extrarenal
diseases, e.g., congestive heart failure, liver diseases and diabetes.
Decreased levels indicate acute hepatic insufficiency or may result from
over-vigorous parenteral fluid therapy.
Simple, direct and automation-ready procedures for measuring urea
concentration or blood urea nitrogen BUN in biological samples are
becoming popular in Research and Drug Discovery. BioAssay Systems'
urea assay kit is designed to measure urea directly in biological samples
without any pretreatment. The improved Jung method utilizes a
chromogenic reagent that forms a colored complex specifically with urea.
The intensity of the color, measured at 520nm, is directly proportional to
the urea concentration in the sample. The optimized formulation
substantially reduces interference by substances in the raw samples.

KEY FEATURES:
Sensitive and accurate. Use 5 μL samples. Linear detection range 0.08
mg/dL (13 μM) to 100 mg/dL (17mM) urea in 96-well plate assay.
Simple and high-throughput. The procedure involves addition of a single
working reagent and incubation for 20 min. Can be readily automated as a
high-throughput assay for thousands of samples per day.
Improved reagent stability and versatility. The optimized formulation has
greatly enhanced reagent and signal stability. Cuvet or 96-well plate assay.
Low interference in biological samples. No pretreatments are needed.
Assays can be directly performed on raw biological samples i.e., in the
presence of lipid and protein.

APPLICATIONS:
Direct Assays: urea in serum, plasma, urine, milk, cell/tissue culture,
bronchoalveolar lavage (BAL) etc.
Drug Discovery/Pharmacology: effects of drugs on urea metabolism.
Environment: urea determination in waste water, soil etc.

KIT CONTENTS: (500 tests in 96-well plates)
Reagent A: 50 mL Reagent B: 50 mL
Urea standard: 1 mL 50 mg/dL
Storage conditions. The kit is shipped at room temperature. Store all
components at 2-8°C. For long-term storage, keep standard at –20°C.
Shelf life: 12 months after receipt.

Precautions: reagents are for research use only. Normal precautions for
laboratory reagents should be exercised while using the reagents.

 Price: 339 EUR

PerkinElmer, Inc., a biotechnology company, on 25 December last year has launched a new range of assay kits utilizing AlphaLISA technology for improving the safety testing, manufacturing and quality control of biotherapeutic drugs.

"PerkinElmer is continuously seeking new ways to improve human health through the development of innovative technologies," said its President - Kevin Hrusovsky. "Adverse reactions due to drug toxicity are a real issue that we are passionate about helping to minimize. We are very excited to enable our customers to improve the safety and efficacy of new biotherapeutic drugs being developed through our new assay kits which are the latest addition to our growing biotherapeutics portfolio."

This kits use the AlphaLISA technology of PerkinElmer's  to achieve higher quality results than the comparable ELISA (enzyme-linked immunosorbent assay) technology in half the time, for accelerating the drug discovery process, the company said.

AlphaLISA technology also has a protocol with fewer assay steps compared to standard ELISA, resulting in better inter-assay and intra-assay precision, improved coefficient of variations (CVs), and easier method transfer to downstream departments due to variability reduction.